

## NIVS Communications 08/04/2022

Dear Colleagues,

### Role Changes

#### Estimated delivery date: w/c 19 April 2022


There will be changes to your roles in NIVS. As a NIVS user, you will see reports assigned to your role that are unique to your role in the system.

These changes will be detailed in a comms closer to the time of release

### Look and Feel Changes

#### Estimated delivery date: w/c 19 April 2022:

Based on your feedback, there will be several changes to the way that NIVS looks implemented e.g., the new front page:



These changes are intended to help improve your experience using NIVS and will be added into an updated version of the User Manual.

These changes will be detailed in a comms closer to the time of release

### **A @nhs.net email required by ALL Superusers**

**Estimated delivery date: 02 May 2022**

To meet a Vaccination Programme requirement, from 2<sup>nd</sup> May 2022 all Superusers requiring access to NIVS **must** have a @nhs.net account.

From this date any Superuser with any email other than this standard will have their account changed from Superusers to a Vaccinator. This will not prevent the administering of vaccines - however you will no longer be able to manage other system users.

Over the coming week, we will be contacting each Superuser that has a different email address directly to assist them with the changeover.

@nhs.co.uk or .gov.uk will no longer be acceptable for the Superuser role.

### **Seven Day Limitation on Vaccination entry**

**Estimated delivery date: w/c 10 May 2022**

To meet a Vaccination Programme requirement, from 10<sup>th</sup> May 2022 there will be a restriction placed on the date that you will be able to input a Covid vaccination into NIVS.

This will mean that from this date, you will not be able to enter a vaccine into the system that was administered more than 7 calendar days ago.

Upcoming comms will provide guidance, help and documentation to support you with this change.

### **Vaccine Name Change:**

**Estimated delivery date: w/c 10 May 2022**

To meet a Vaccination Programme requirement, the current AstraZeneca vaccine will be renamed in NIVS to:

Vaxzevria 0.5ml dose (AstraZeneca)

This will align the current Astrazeneca vaccine naming conventions to match other current Covid vaccines.

e.g. Spikevax 0.1mg/0.5ml dose (Moderna)

Comirnaty 30micrograms/0.3ml dose (Pfizer) .


**Multi Factor Authentication:**

**Estimated delivery date: w/c 10 May 2022**

To enhance the security of NIVS, we will be requiring Superusers to identify themselves by more than just a username and password.

This will be in form of a PIN that will need to be entered into the logon screen of NIVS.

Please look out for upcoming communications from your SPOC that will contain the process to register for MFA and how to use it.



Kind regards,

**National Immunisation & Vaccination System Support Team**

Telephone: **0121 611 0187**

Email: [nivs@england.nhs.uk](mailto:nivs@england.nhs.uk)

Web: <http://nivs.ardengemcsu.nhs.uk/home>

---

This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this email, or any disclosure or copying of its content, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.



Please consider the environment before printing this e-mail.